TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04178278

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Shuttle walking test
Description: Patients will be required to walk around a 10-m course marked by cones placed 9 m apart, thus allowing 0.5 m for turning at each end. Walking speed will be regulated by prerecorded signals on a compact disc or MP3 file. Patients will increase walking speed at every minute. patients can stop this study, when they can not maintain their speeds due to dyspnea

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Exercise stress test
Description: Exercise stress test will be performed with cycle. When patients perform this study, they will gradually increase the velocity. Investigators will measure electrocardiography, vital sign, oxygen saturation, oxygen uptake, minute ventilation and fatigue.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 6 minutes walking test
Description: When participants perform 6 minutes walking test, patients will walk around the tract during 6 minutes. They can their walking speed according to condition and symptom. Investigators records walking distance, pulse rate, oxygen saturation and Borg scale
Study: NCT02224248

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health checks with fitness testing
Description: Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health checks without fitness testing
Description: The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
Study: NCT02103296

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drawing admission labs from cord blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drawing admission labs from infant blood
Study: NCT04721587

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The patients of the VR Group will be subjected to the same hysteroscopy technique as the Standard of Care Group, but additionally a VR device will be applied where a distraction VR environment (Underwater Game) will be reproduced during the exploration
Study: NCT02121613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permixon® 160 mg
Description: Oral administration - 160 mg twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Tamsulosine LP
Description: Oral administration - 0.4 mg daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Permixon® 160 mg
Description: Oral administration - twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Tamsulosine LP
Description: Oral administration - daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching Tamsulosine LP
Description: Oral administration - daily.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo matching Tamsulosine LP
Description: Oral administration - daily.
Study: NCT02499445

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: administering remifentanil for anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: administering remifentanil for anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 1
Description: administering sevoflurane 1 for anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane 2
Description: administering sevoflurane 2 for anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: administering propofol for anesthesia maintenance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: administering sufentanil for anesthesia maintenance
Study: NCT02669485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indocyanine green
Description: Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence imaging
Study: NCT00512057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: allopurinol
Description: allopurinol 300mg twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT00348881

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTaP-HB-PRP~T combined vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB/Hib™ vaccine
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral poliomyelitis vaccine (OPV)
Description: Oral co-administered with study vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral poliomyelitis vaccine (OPV)
Description: Oral co-administered with study vaccine.
Study: NCT00123669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 500 mg of depot hydroxy-progesterone
Description: An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
Study: NCT01848041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 0.1% Ophthalmic Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 0.1% Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: RVL-1201 Vehicle Placebo
Description: RVL-1201 Vehicle Placebo
Study: NCT03079960

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrophysiological recording and measurement devices
Description: Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
Study: NCT03144609

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: low PEEP
Description: The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARM
Description: The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ARM
Description: The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high PEEP
Description: The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: high PEEP
Description: The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
Study: NCT03255083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1205c
Description: DS-1205c 200 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib 80 mg tablet
Study: NCT01046409

Intervention type: OTHER
Intervention: Measuring collateral flow
Description: Measuring collateral flow using pressure and/or velocity coronary wire
Study: NCT03230019

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: chest tube
Description: VATS with chest tube placement

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two-lumen catheterization
Description: VATS with two-lumen catheterization long the midclavicular line, second intercostal space

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: two-lumen catheter
Description: central venous catheter(two-lumen 7-Fr-20cm)
Study: NCT02997306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Superior/Medial Running Sutures
Description: Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior/Lateral Running Sutures
Description: Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
Study: NCT03207763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Formulation 1
Description: Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle Formulation 2
Description: Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be \<1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).~Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches.
Study: NCT03278067

Intervention type: OTHER
Intervention: Enhanced vaccine safety surveillance
Description: Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.

Intervention type: OTHER
Intervention: Enhanced vaccine safety surveillance
Description: Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.

Intervention type: OTHER
Intervention: Enhanced vaccine safety surveillance
Description: Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
Study: NCT00667108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 250 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 500 mg oral capsule 30 minutes prior to bedtime

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo 30 minutes prior to bedtime
Study: NCT03624010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan 2.5 mg/ml Injectable Solution
Description: A sterile 2.5 mg/mL concentrate solution that is diluted in 5% Dextrose or 0.9 Normal Saline to achieve a 50 microgram/min solution for infusion
Study: NCT01865552

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB4
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB4
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB4
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB4
Description: SC administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EU sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EU sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EU sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: EU sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: US sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: US sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: US sourced Enbrel
Description: SC administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: US sourced Enbrel
Description: SC administration
Study: NCT01027806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: 1 pill per day for 4 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast
Description: 1 pill per day for 4 months
Study: NCT02923921

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegilodecakin
Description: Pegilodecakin plus FOLFOX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX
Description: FOLFOX Alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX Alone
Study: NCT05906290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multigenerational eHealth Intervention for Grandparents and Grandchildren
Description: Participants in this group will use an online program for 30-45 minutes per week over the course of 2 weeks delivered via smartphone, focusing on increasing physical activity.
Study: NCT04591678

Intervention type: DRUG
Intervention: nusinersen
Description: SPINRAZA (nusinersen) is FDA approved to treat spinal muscular atrophy (SMA) through intrathecal injection.
Study: NCT03329014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: For induction and maintenance of sedation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control arm
Study: NCT01680029

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBASE-system 2.0
Study: NCT01326338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
Study: NCT04398095

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: Resectable or marginally resectable tumors: preoperative hypofractionated 12x 3 Gy radiotherapy (4 days in a week, three weeks) prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with daily image guidance with cone beam-CT or kV-portal position verification.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperthermia
Description: Deep hyperthermia (Celsius TCS or BSD-2000) according to local protocol combined with radiotherapy, twice a week.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy with boost
Description: Non-resectable/inoperable tumors: definitive hypofractionated 12x 3 Gy radiotherapy prescribed on planned target volume (tumor volume + elective margins + setup/error margin) with simultaneous integrated boost 3.5 Gy per fraction prescribed on boost planned target volume (tumor volume + setup/error margin), 4 days in a week, three weeks.~Radiotherapy with daily image guidance with cone beam-CT or kV-portal position verification.
Study: NCT04480970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasogastric tube placement
Description: All patients enrolled in the study will have a nasogastric tube placed for gastric decompression.
Study: NCT03637088

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude (FiO2: 15.1%)
Description: Inhalation of deoxygenated air through a altitude simulator (Altitrainer), for approx. 1 hour. given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask
Study: NCT04183361

Intervention type: DIAGNOSTIC_TEST
Intervention: ABR and salivary cortisone testing
Description: Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold.

Intervention type: DIAGNOSTIC_TEST
Intervention: ABR and salivary cortisone testing
Description: Three saliva samples at the workplace will be collected immediately after the morning shift. The first saliva sample was given 3 days (Tuesday) before arrival at the research place, the second sample 2 days (Wednesday) before arrival, and the third sample 1 day (Thursday) before arrival at the research site. One hour before saliva sampling, a respondent should not brush his/her teeth nor eat nor drink. Fifteen minutes prior to sample administration, the subject should rinse his/her mouth with a cold water. Samples will be analyzed using High Performance Liquid Chromatography (HPLC) at the Translational Medicine Division of the Srebrnjak Children's Hospital.~2. Collaboration in the process of assessing hearing health at the research place. The assessment includes: otoscopy, tympanometry and audiometry. Subjects will be tested for auditory evoked brainstem response in only one ear, with a more regular hearing threshold.
Study: NCT03856281

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression
Description: Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression
Description: Participants administer an intermittent pneumatic compression device in addition to their standard lymphoedema care for a 5 week treatment period